ATAGI update following weekly Covid meeting 3 February

Department of Health

ATAGI update tile

Latest recommendation updates:

  • ATAGI provided advice on Pfizer boosters for individuals aged 16-17 years.

Recent ATAGI considerations

On Wednesday 2 February 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As at 2 February 2022, over 50 million doses of COVID-19 vaccines have been administered in Australia. ATAGI encourages anyone aged 16 years and over to receive a booster dose as soon as they are eligible.

Boosters for adolescents aged 16-17 years

ATAGI recommends a booster vaccination with Comirnaty (Pfizer) COVID-19 vaccine, for all adolescents aged 16-17 years who have previously received any TGA approved or recognised vaccines for their primary vaccine schedule. This booster dose is available from 3 months after receiving their last primary dose.

The Pfizer vaccine is the only brand currently registered for use as a booster dose in this age group. ATAGI will update this advice if other vaccines are approved.

Full details of ATAGI’s advice is available.

Upcoming ATAGI considerations

ATAGI is continuing to monitor evidence on the vaccine effectiveness of boosters and national coverage rates.

COVID-19 vaccine safety

Th ATAGI COVID-19 Safety Group will meet again this week to monitor known and emerging serious adverse events following immunisation and other safety issues in the delivery of COVID-19 vaccines. The ATAGI COVID-19 Safety Group provides regular updates to the ATAGI COVID-19 Working Group. The TGA’s Weekly Report provides a detailed breakdown of adverse events following immunisation.

Resources and recent statements

ATAGI recommends review of the following key resources:

/Media Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.